Summary
Regeneron Pharmaceuticals, Inc. filed an amendment to its June 14, 2017, 8-K report. This amendment serves to formally disclose the company's decision regarding the frequency of advisory shareholder votes on executive compensation. The primary purpose of this filing is regulatory compliance and to update shareholders on this specific governance matter. Following a shareholder vote at the 2017 Annual Meeting on June 9, 2017, the proposal to hold advisory shareholder votes on executive compensation every three years received a majority of the votes cast. Consequently, Regeneron's Board of Directors, acting on recommendations from its Compensation Committee and Corporate Governance and Compliance Committee, has determined that these advisory votes will continue to be held once every three years.
Key Highlights
- 1Regeneron filed an 8-K/A amendment to a previous filing from June 14, 2017.
- 2The amendment clarifies the frequency of advisory shareholder votes on executive compensation.
- 3Shareholders voted on the frequency of these advisory votes at the 2017 Annual Meeting.
- 4A majority of votes cast supported holding advisory votes on executive compensation every three years.
- 5Regeneron's Board of Directors has decided to continue holding these advisory votes triennially.
- 6This decision aligns with shareholder sentiment and committee recommendations.
- 7The filing is primarily for disclosure and regulatory compliance purposes.